Oxford, United Kingdom — Oxford Medical Diagnostics (OMD), the developer of breath-based, medical diagnostic technology for the rapid, non-invasive, accurate and low-cost diagnosis and monitoring of metabolic and infectious diseases; and Absam, Austria-based V&F Analyse- und Messtechnik GmbH (V&F), a provider of analytical instruments to a wide range of industries, today announced a strategic alliance focusing on the area of mass spectrometry.
Under the terms of the new agreement with V&F, Oxford Medical Diagnostics will offer and support V&F’s high-performance mass spectrometry analyzers in the UK and Ireland. Also, OMD will establish a contract batch sample analysis service in its Oxford laboratories to provide analytical services to third party customers using V&F’s mass spectrometers.
OMD will bring to bear its expertise in spectrometry and is itself developing the Acetone Breath Analyzer, based on its proprietary infrared absorption spectroscopy. The device will be used to screen and diagnose Type 1 and Type 2 diabetes, as well as monitor weight-loss in healthy individuals.
Target markets for mass spectrometry and allied contract analytical services are substantial. They include pharmaceuticals, biotechnology, aerospace, fine chemicals, oil and gas, the environment, and food and beverages. OMD already uses V&F’s leading mass spectrometry technology as the gold standard with which to compare clinical results from diabetic patients with OMD’s proprietary laser based breath analysis solutions. The joint offering now implies a much closer working relationship between the two companies.
In addition to this collaboration, the two companies are looking into other opportunities for joint research. These include bacterial headspace analysis – analyzing the space above bacteriological samples such as MRSA and Clostridium difficile – as well as sports performance monitoring and healthy weight loss management.
“This is a great alliance for OMD, linking us to one of the most talented molecular analysis companies in the world. It brings analytical know-how, and the opportunity to earn revenues – an important discipline for early-stage companies, like ours,” said Oxford Medical Diagnostics CEO, Tony Marchington.
“We project an exciting future working with OMD,” said Dr Werner Federer, president of V&F. “Diabetes and lifestyle-weight loss represent significant opportunities for both our companies.”
SOURCE: Oxford Medical Diagnostics